Related ArticlesNeoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother. 2020 Apr 01;:1-12 Authors: Montemurro F, Nuzzolese I, Ponzone R Abstract Introduction: The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field.Areas...
Fri Apr 03, 2020 15:14
Related ArticlesrBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma. FEBS Open Bio. 2020 Mar 31;: Authors: Mawaribuchi S, Haramoto Y, Tateno H, Onuma Y, Aiki Y, Ito Y Abstract The recombinant N-terminal domain of BC2L-C lectin (rBC2LCN) is useful for detecting not only human pluripotent stem cells but also some cancers. However, the cancer types and stages that can be detected by rBC2LCN remain unclear. In this study, we...
Fri Apr 03, 2020 13:18
Related ArticlesHER2 borderline is a negative prognostic factor for primary malignant breast cancer. Breast Cancer Res Treat. 2020 Mar 31;: Authors: Bhattacharjee A, Rajendra J, Dikshit R, Dutt S Abstract BACKGROUND: HER-(human epidermal growth factor receptor 2) gene amplification and protein overexpression are important predictive, prognosis markers, and therapeutic target for breast cancer, emphasizing the importance of categorizing patients into...
Fri Apr 03, 2020 13:18
Related ArticlesResponse of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. J Clin Med. 2020 Mar 30;9(4): Authors: Keung MY, Wu Y, Badar F, Vadgama JV Abstract Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven to be beneficial to patients with metastatic breast cancer with BRCA1/2 (BReast CAncer type 1 and type 2 genes) mutations. However, certain PARPi in pre-clinical studies have been shown to inhibit cell growth and...
Fri Apr 03, 2020 13:18
Related ArticlesOptimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer. Anticancer Res. 2020 Apr;40(4):2303-2309 Authors: Kuba S, Maeda S, Matsumoto M, Yamanouchi K, Iwata T, Morita M, Sakimura C, Otsubo R, Yano H, Sato S, Kanetaka K, Nagayasu T, Eguchi S Abstract BACKGROUND/AIM: To predict pCR during neoadjuvant chemotherapy is still difficult. The aim of this study was to evaluate the optimal tumor reduction rate...
Fri Apr 03, 2020 13:18
Related ArticlesSignificant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review. Cancer Biol Ther. 2020 Apr 01;:1-7 Authors: Danni L, Lingyun Z, Jian W, Hongfei Y, Lu X, Peng Y, Xiujuan Q, Yunpeng L, Yuee T Abstract Although HER2-targeted therapy has been shown to prolong the survival of patients with HER2-positive breast cancer, most patients eventually progress due to drug...
Fri Apr 03, 2020 13:18
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου